Two Sigma Investments’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$738K Sell
48,137
-18,957
-28% -$349K ﹤0.01% 3801
2026
Q2
$1.24M Buy
67,094
+2,669
+4% +$42.2K ﹤0.01% 3443
2026
Q1
$962K Sell
64,425
-133,212
-67% -$2.08M ﹤0.01% 3288
2025
Q4
$2.69M Buy
148,237
+98,995
+201% +$1.67M ﹤0.01% 2217
2025
Q3
$626K Buy
49,242
+36,353
+282% +$313K ﹤0.01% 2879
2025
Q2
$64.3K Buy
+12,889
New +$60.2K ﹤0.01% 3046
2022
Q2
– Sell
-25
Closed -$51K – 2504
2022
Q1
$51K Sell
25
-78
-76% -$196K ﹤0.01% 2486
2021
Q4
$503K Sell
103
-151
-59% -$906K ﹤0.01% 3255
2021
Q3
$1.6M Sell
254
-140
-36% -$1.13M ﹤0.01% 2190
2021
Q2
$3.71M Buy
394
+158
+67% +$1.32M 0.01% 1387
2021
Q1
$2.05M Buy
236
+71
+43% +$671K 0.01% 1690
2020
Q4
$1.25M Sell
165
-40
-20% -$278K ﹤0.01% 1822
2020
Q3
$1.34M Buy
205
+115
+128% +$864K ﹤0.01% 1564
2020
Q2
$672K Buy
+90
New +$653K ﹤0.01% 1793

Other funds holding AVTX

Two Sigma Investments's AVTX Position: Q3 2026 in Review

Two Sigma Investments reduced its Avalo Therapeutics (AVTX) stake by 28% in Q3 2026, selling an estimated $349K and leaving 48,137 shares worth $738K. The position accounts for ﹤0.01% of the portfolio, ranked #3801.

Two Sigma Investments first reported a position in AVTX in Q2 2020 and has held it in 14 quarters since. The position peaked at $3.71M in Q2 2021. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Two Sigma Investments held 48,137 shares of Avalo Therapeutics worth $738K as of Q3 2026.
  • Two Sigma Investments sold 18,957 Avalo Therapeutics shares in Q3 2026, an estimated $349K.
  • Avalo Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q3 2026, its #3801 holding.
  • Two Sigma Investments first reported a position in Avalo Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • Two Sigma Investments's Avalo Therapeutics position peaked at $3.71M in Q2 2021.
  • 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Two Sigma Investments's 13F filing for Q3 2026, filed 16 Nov 2026.